Cyproterone
Cyproterone is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dianeal low calcium peritoneal dialysis solution with dextrose dianeal pd-2 peritoneal dialysis solution with dextrose | New Drug Application | 2013-06-30 |
| dianeal low calcium with dextrose | unapproved drug for use in drug shortage | 2025-07-02 |
| dianeal low calcium with dextrose dianeal pd-2 with dextrose | New Drug Application | 2026-04-16 |
| dianeal pd-2 peritoneal dialysis solution with dextrose | New Drug Application | 2010-06-07 |
| emme diane pure protection tinted antioxidant sunscreen | C200263 | 2025-01-16 |
| emme diane tinted mineral sunscreen | C200263 | 2025-01-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 2 | 1 | 8 | 7 | 18 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 3 | 3 | 7 |
| Gender dysphoria | D000068116 | — | F64 | — | — | — | 1 | 5 | 6 |
| Hyperandrogenism | D017588 | — | — | — | — | — | 3 | 1 | 4 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | 1 | 2 | 4 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | — | 1 | 1 | 2 |
| Menstruation disturbances | D008599 | — | N91.5 | — | — | — | 2 | — | 2 |
| Transsexualism | D014189 | — | F64.0 | — | — | — | 2 | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Overweight | D050177 | — | E66.3 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | 5 | — | 3 | 9 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 2 | — | — | 2 |
| Hot flashes | D019584 | — | — | — | 1 | 1 | — | — | 2 |
| Perimenopause | D047648 | — | — | — | 1 | 1 | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | — | 1 | — | — | 1 |
| Pedophilia | D010378 | — | F65.4 | — | — | 1 | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | 1 | — | — | 1 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | 1 | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 1 | — | — | — | 1 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | 1 | — | — | — | 1 |
| Premature menopause | D008594 | — | E28.31 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | — | 1 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | — | — | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Alopecia | D000505 | — | L64 | — | — | — | — | 2 | 2 |
| Seborrheic dermatitis | D012628 | — | L21 | — | — | — | — | 2 | 2 |
| Hirsutism | D006628 | — | L68.0 | — | — | — | — | 2 | 2 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 2 | 2 |
| Gingivitis | D005891 | — | K05.10 | — | — | — | — | 2 | 2 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | — | — | — | — | — | — | 1 | 1 |
| Pelvic pain | D017699 | — | — | — | — | — | — | 1 | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | — | 1 | 1 |
Show 18 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cyproterone |
| INN | cyproterone |
| Description | Cyproterone acetate is a steroid ester resulting from the formal condensation of the carboxy group of acetic acid with the 17-hydroxy group of cyproterone. It is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It has a role as an androgen antagonist, a progestin and a geroprotector. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid, a chlorinated steroid, a steroid ester and an acetate ester. It is functionally related to a cyproterone. |
| Classification | Small molecule |
| Drug class | antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 427-51-0 |
| RxCUI | 22054 |
| ChEMBL ID | CHEMBL139835 |
| ChEBI ID | 50743 |
| PubChem CID | 9880 |
| DrugBank | DB04839 |
| UNII ID | E61Q31EK2F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
145,305 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use